Successful Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection with Meropenem and Cefoperazone Sodium Sulbactam: A Case Report.

IF 2.9 3区医学 Q2 INFECTIOUS DISEASES

Infection and Drug Resistance Pub Date : 2025-04-04 eCollection Date: 2025-01-01 DOI:10.2147/IDR.S495491

Wenke Ma, Chao Zhang, Bei He, Xinwen Lv, Peng Luo

{"title":"Successful Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection with Meropenem and Cefoperazone Sodium Sulbactam: A Case Report.","authors":"Wenke Ma, Chao Zhang, Bei He, Xinwen Lv, Peng Luo","doi":"10.2147/IDR.S495491","DOIUrl":null,"url":null,"abstract":"Background: Acinetobacter baumannii intracranial infections, especially those caused by multidrug-resistant (MDR) or extensively drug-resistant (XDR) strains, have posed an increasing challenge to treatment because of poor drug permeability through the blood-brain barrier (BBB) and increased bacterial drug resistance. Therefore, we aimed to explore a therapeutic schedule for Acinetobacter baumannii intracranial infection.Case presentation: We reported a case of intracranial infection caused by XDR A. baumannii after severe traumatic brain injury, cerebrospinal fluid (CSF) rhinorrhea, and severe pneumonia that was successfully treated with meropenem and cefoperazone sodium sulbactam.Conclusion: This case illustrated that meropenem combined with cefoperazone sodium sulbactam could still be a therapeutic option against intracranial XDR A. baumannii infection.","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"1721-1727"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977545/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IDR.S495491","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Acinetobacter baumannii intracranial infections, especially those caused by multidrug-resistant (MDR) or extensively drug-resistant (XDR) strains, have posed an increasing challenge to treatment because of poor drug permeability through the blood-brain barrier (BBB) and increased bacterial drug resistance. Therefore, we aimed to explore a therapeutic schedule for Acinetobacter baumannii intracranial infection.

Case presentation: We reported a case of intracranial infection caused by XDR A. baumannii after severe traumatic brain injury, cerebrospinal fluid (CSF) rhinorrhea, and severe pneumonia that was successfully treated with meropenem and cefoperazone sodium sulbactam.

Conclusion: This case illustrated that meropenem combined with cefoperazone sodium sulbactam could still be a therapeutic option against intracranial XDR A. baumannii infection.

查看原文本刊更多论文

背景：鲍曼不动杆菌颅内感染，尤其是由耐多药（MDR）或广泛耐药（XDR）菌株引起的颅内感染，由于通过血脑屏障（BBB）的药物渗透性差以及细菌耐药性的增加，给治疗带来了越来越大的挑战。因此，我们旨在探索鲍曼不动杆菌颅内感染的治疗方案：我们报告了一例由 XDR 鲍曼不动杆菌引起的颅内感染病例，患者在严重脑外伤、脑脊液（CSF）鼻出血和重症肺炎后接受美罗培南和头孢哌酮钠舒巴坦钠治疗获得成功：本病例表明，美罗培南联合头孢哌酮钠舒巴坦钠仍然是治疗颅内XDR鲍曼不动杆菌感染的一种选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infection and Drug Resistance Medicine-Pharmacology (medical)

CiteScore

5.60

自引率

7.70%

发文量

826

审稿时长

16 weeks

期刊介绍： About Journal Editors Peer Reviewers Articles Article Publishing Charges Aims and Scope Call For Papers ISSN: 1178-6973 Editor-in-Chief: Professor Suresh Antony An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.